LLS Leader Discusses Technology Efforts in the Organization

0
(0)

 

The Leukemia and Lymphoma Society (LLS) is a leading organization that fights blood cancer and works to improve the lives of patients and their loved ones. In this interview, the SVP and CIO of the Leukemia and Lymphoma Society, Claude Edkins discusses the organization’s strategy and how it manages to overcome obstacles like bureaucracies to do their work and pursue their mission.

“We have made some very large strategic decisions over the past few years,” stated Edkins in the interview with Peter Coffee, Head of Platform Research, and Julie Hansen, Principal Solution Engineer, which took place during the Salesforce World Tour New York 2016 Keynote Pre-Show.

The SVP and CIO explained that by using new platforms, the LLS work is now very facilitated. When asked about any advice for other organizations who find it difficult to bring technology into their work, Edkins declared: “Reduce the complexity.”

Stay updated with the latest lymphoma news here: http://bit.ly/1UwWKe6

Lymphoma News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
×
Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
Latest Posts
  • ATG-019 Phase 1 trial
  • ME-401, FDA fast track
  • Tafasitamab combo, lymphoma
  • blood biomarkers

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Leave a Comment

Your email address will not be published. Required fields are marked *